| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Aug 2025 | 6 Aug 2025 |
| Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2025. 2. Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. Tuesday, 12th August, 2025 have 1. Approved the Unaudited Financial Results of the Company for the quarter ended 30th June, 2025. The Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. 2. Approved the appointment of Mr. Arvind Vilasrao Sapkal (DIN- 08607096) as a Non- executive Independent Director of the Company, for a Second term of 5 (Five) consecutive years, which is subject to the approval of the shareholders of the Company. 3.Considered and approved the amendment in the Notice for convening the 32nd Annual General Meeting of the Company. 4. Board have approved the proposal to capitalize on any business opportunity in other field that may arise from time to time, provided the said business activity is included in MOA of the Company. Unaudited Financial Results of the company for the quarter ended 30th june, 2025 along with limited review report issued by the statutory auditor of the Company. (As Per BSE Announcement Dated on:12.08.2025) | ||
| Board Meeting | 13 Jun 2025 | 10 Jun 2025 |
| Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/06/2025 inter alia to consider and approve 1. To Update regarding the current business operations of the Company. 2. Any other matter with permission of the Chair. Update on current business operations of the Company (As per BSE Announcement Dated on 13/06/2025) | ||
| Board Meeting | 30 May 2025 | 23 May 2025 |
| Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve 1. The Audited Financial Results of the Company for the quarter and year ended 31st March 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 32nd Annual General Meeting of the Company. 3. To consider the appointment of M/s Meenu Maheshwari & Associates Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2025-26. 4. To consider the re-appointment of Mr. Arvind Sapkal [DIN: 08607096] for the further term of Five years as an Independent Non-Executive Director of the Company. 5. To consider the re-appointment of Internal Auditors of the Company for the year 2025-26. 6. To take on record Disclosure of Interest of Directors. 7. Any other matter with permission of the Chair. Outcome of Board Meeting held on 30th May, 2025 Audited Financial Results for the quarter and year ended on 31st March, 2025. (As per BSE Announcement Dated on 30/05/2025) | ||
| Board Meeting | 13 Feb 2025 | 6 Feb 2025 |
| ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 31st December 2024. 2. Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e.13th February, 2025 have 1. Approved the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2024. and the Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. Approval of the Unaudited Financial Results of the Company for the quarter ended 31st December, 2024, the limited review report issued by statutory auditor of the company attached herewith. (As Per BSE Announcement Dated on 13.02.2025) | ||
| Board Meeting | 12 Nov 2024 | 6 Nov 2024 |
| ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve 1.To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2024. 2.Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 12th November, 2024 have 1. Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2024. The Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. 2. Acceptance of the Resignation received from Mr. Govind Madanlal Gupta [DIN: 00052690], non-executive independent Director of the Company, due to his pre-occupation and other professional commitments, with effect from close of business hours on 12th November, 2024. Read less.. (As Per BSE Announcement Dated on: 12/11/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.